105803-39-2

Upstream product

• 105880-38-4 (1S)-1-cyclohexyl-2-propyn-1-ol 
• 97563-45-6 1-cyclohexylprop-2-yn-1-ol 
• 7560-69-2 1-cyclohexyl-2-propyn-1-one 
• 288-32-4 1H-imidazole 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 2043-61-0 cyclohexanecarbaldehyde 

Downstream Products

• 105803-40-5 3-hydroxy acetal silyl ether 
• 105880-44-2 C₂₅H₄₂O₄Si 
• 105880-45-3 C₂₅H₄₂O₄Si 
• 105803-42-7 (3'S,1S,2S,3R,6S)-2-(3'-cyclohexyl-3'-hydroxyprop-1'-ynyl)-3-hydroxybicyclo<4.2.0>octan-7-one 
• 108147-33-7 (1R,2S,3R,6S)-2-((R)-3-Cyclohexyl-3-hydroxy-prop-1-ynyl)-3-hydroxy-bicyclo[4.2.0]octan-7-one 
• 108147-32-6 (1S,2R,3S,6R)-2-((R)-3-Cyclohexyl-3-hydroxy-prop-1-ynyl)-3-hydroxy-bicyclo[4.2.0]octan-7-one 
• 108147-34-8 (1S,2R,3S,6R)-2-((S)-3-Cyclohexyl-3-hydroxy-prop-1-ynyl)-3-hydroxy-bicyclo[4.2.0]octan-7-one 
• 105284-21-7 butanoic acid, 4-[(1S,2S,3R,6S)-2-[(3S)-3-cyclohexyl-3-hydroxy-1-propynyl]-3-hydroxybicyclo[4.2.0]oct-7-ylidene]-(4Z) 
• 105880-50-0 4-[(1S,2S,3R,6S)-2-((S)-3-Cyclohexyl-3-hydroxy-prop-1-ynyl)-3-hydroxy-bicyclo[4.2.0]oct-(7E)-ylidene]-butyric acid 
• 105880-66-8 RS₉₃₅₂₀ 

Relevant academic research and scientific papers

Novel 6-alkyl and 6.8-dialkylbicyclo(4.2.0)octane derivatives

Compounds useful in treating or preventing gastrointestinal ulcers and in treating cardiovascular disorders such as thrombosis, hypertension and atherosclerosis are depicted in formulas (1), (2) and (3): STR1 wherein: A is --C C--, trans --HC=CH--, trans --CH=CHCH2 -- or --CH2 CH2 --; X is lower alkyl of 1-6 carbon atoms; Y is hydrogen, exo-(lower alkyl) or endo-(lower alkyl); n is an integer from 2-4; R1 is --CH2 OH, --CHO, --CO2 R or --CO2 H, and the olefin formed by the R1 (CH2)n CH= moiety is either (E) or (Z); R2 is hydrogen or methyl, or optionally --CH=CH2 when A is trans --CH=CHCH2 --; and R3 is linear or branched alkyl, alkenyl or alkynyl having 5-10 carbon atoms, STR2 --(CH2)m -phenyl or CH2 O-phenyl; in which each phenyl may be optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen. in which: a is an integer of 0, 1 or 2; b is an integer of 3-7; m is an integer of 0, 1 or 2; and R is STR3 wherein X' is STR4 in which each R4 is independently hydrogen or lower alkyl having 1-6 carbon atoms, or a pharmaceutically acceptable, non-toxic salt or ester thereof.

Process and intermediates for the synthesis of the enantiomers of bicyclo(4.2.0)oct-2-en-7-one and derivatives and for the synthesis of bicyclo(4.2.0)octane derivatives

The enantiomers of formulas are prepared in a sequence starting from the racemic compound of formula wherein X is hydrogen or bromo when Y is bromo, or X is chloro when Y is chloro. The key step of this process involves a microbial reduction of the compou

Potent Prostacyclin Analogues Based on the Bicyclooctane Ring System

The novel and biologically active prostacyclin mimetics 2 and 29 were prepared in a sequence based on the regioselective opening of epoxide 7 with a lithium acetylide in the presence of boron trifluoride etherate.The regioselectivity of epoxide opening wa